Peptide stacks · Weight and metabolism
5-Amino-1MQ and retatrutide stack: what’s in it and the evidence
Checked against our library and study pagesPublished by PepVault
The 5-Amino-1MQ and retatrutide stack is two compounds run side by side, each from its own vial or form: 5-Amino-1MQ and retatrutide. The library records 5-Amino-1MQ at 50–100 mg and retatrutide at 1–12 mg per dose as reference ranges.
This page describes what the crowd runs and what a vial holds. It recommends no stack and names no seller.
What’s in the 5-Amino-1MQ and retatrutide stack
| Part | Reference range | Filed under | Evidence (library) |
|---|---|---|---|
| 5-Amino-1MQ | 50–100 mg | Fat metabolism, NAD+ boost, Lean mass preservation | Emerging |
| Retatrutide | 1–12 mg | Triple-agonist, Highest weight loss, Energy expenditure | Established |
The library’s reference range per dose, part by part
5-Amino-1MQ
5-Amino-1MQ is one of the two parts of the 5-Amino-1MQ and retatrutide stack. A small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy.
Retatrutide
Retatrutide is one of the two parts of the 5-Amino-1MQ and retatrutide stack. The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).

Model. Individual results vary.
Has the 5-Amino-1MQ and retatrutide stack been studied as a combination?
None of our 436 study pages tested 5-Amino-1MQ and retatrutide together, so the 5-Amino-1MQ and retatrutide stack rests on studies of its parts and on community reports.
The studies of the parts, one by one: 3 study pages on 5-Amino-1MQ (0 in people) and 16 study pages on retatrutide (12 in people).
| Part | Study pages | In people | Strongest study page |
|---|---|---|---|
| 5-Amino-1MQ | 3 | 0 | 5-Amino-1MQ slowed bladder tumor growth in mice (animal study, 2024) |
| Retatrutide | 16 | 12 | Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis (meta-analysis, 2026) |
What people commonly report on the 5-Amino-1MQ and retatrutide stack
The library holds no report of what people notice on the 5-Amino-1MQ and retatrutide stack as a pair. What it records for each part on its own:
- 5-Amino-1MQ: nothing to feel, though some describe easier fat loss alongside a deficit or a GLP-1.
- Retatrutide: appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate.
These are reports from people who run it, collected in the library, not results from a trial and not a promise of what any one person will notice.
Why these are combined
“5-Amino-1MQ + Retatrutide target intake and fat metabolism”, the library’s note on the pair (community report)
5-Amino-1MQ inhibits NNMT (an enzyme that, when overactive, slows fat metabolism); Retatrutide cuts appetite and intake.
How the parts of the 5-Amino-1MQ and retatrutide stack are mixed and taken
The 5-Amino-1MQ and retatrutide stack isn’t one pre-mixed vial in the library: each part has its own route and schedule, as its entry records them.
| Part | Route | How often | Our vial pages |
|---|---|---|---|
| 5-Amino-1MQ | Oral | Daily | No vial page |
| Retatrutide | SubQ injection | Weekly | 5 mg vial, 10 mg vial, 15 mg vial, 20 mg vial, 24 mg vial, 30 mg vial, 40 mg vial, 60 mg vial |
Our vial pages work out the mix for each part’s own vial, size by size:
Compared with running the parts apart
The library’s notes on the 5-Amino-1MQ and retatrutide stack don’t compare it with running either part on its own.
Safety notes
The library holds no combination safety note on the 5-Amino-1MQ and retatrutide stack, so each part’s own notes apply, on its compound page.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Questions people ask
What is in the 5-Amino-1MQ and retatrutide stack?
The 5-Amino-1MQ and retatrutide stack is two compounds run side by side, each from its own vial or form: 5-Amino-1MQ and retatrutide. The library records 5-Amino-1MQ at 50–100 mg and retatrutide at 1–12 mg per dose as reference ranges.
Has the 5-Amino-1MQ and retatrutide stack been studied together?
Not as a combination in any of our study pages: the 5-Amino-1MQ and retatrutide stack rests on studies of its parts and on community reports.
Do the parts of the 5-Amino-1MQ and retatrutide stack come in one vial?
No: in the library each part of the 5-Amino-1MQ and retatrutide stack is its own compound with its own route and schedule (5-Amino-1MQ by Oral and retatrutide by SubQ injection).
What does each part of the 5-Amino-1MQ and retatrutide stack do?
5-Amino-1MQ: A small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy. Retatrutide: The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).